Country: Canada
Language: English
Source: Health Canada
TEMOZOLOMIDE
ACCORD HEALTHCARE INC
L01AX03
TEMOZOLOMIDE
140MG
CAPSULE
TEMOZOLOMIDE 140MG
ORAL
5/20
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0138781006; AHFS:
APPROVED
2014-07-23
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ACH-TEMOZOLOMIDE Temozolomide capsules Capsules, 5 mg, 20 mg, 100 mg, 140 mg, and 250 mg, Oral USP Antineoplastic Agent Accord Healthcare, Inc., 3535 boul. St. Charles, suite 704, Kirkland, QC, H9H 5B9, Canada Date of Initial Authorization: July 24, 2012 Date of Revision: February 17, 2023 Submission Control Number: 268934 _ACH-TEMOZOLOMIDE (temozolomide) _ _ _ _Page 2 of 53_ RECENT MAJOR LABEL CHANGES 7 WARNING AND PRECAUTIONS, Reproductive Health: Females and Males Potential 02/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS................................................................................................................... 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 4 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ............................................................ 5 4.4 Administration ................... Read the complete document